With disease progression, the need to intensify therapy with insulin is often required in patients with T2D to improve glycemic control. Addressing the manner in which insulin is delivered may impact outcomes. The purpose of this study was to broadly evaluate the clinical benefits of switching from insulin delivery via insulin pen/syringe to a wearable insulin delivery device (V-Go) in patients with T2D across multidisciplinary investigators spanning 8 states. A retrospective analysis of electronic medical records evaluated change in A1C, insulin total daily dose (TDD) and weight in 283 patients. Baseline mean ± SD characteristics were A1C 9.2 ± 1.5%, BMI 34.8 kg/m2 ± 6.7, weight 221 ± 45 lbs and TDD 76 ± 47 u/day (range 14 to 300) with basal-bolus (n=192, 68%), basal (n=64, 23%) and premix (n=15, 5%) regimens being predominately prescribed. Concomitant anti-hyperglycemic agents were prescribed in 77% of patients with a mean of 1.7 ± 0.8 agents/patient prescribed. Effect of V-Go was evaluated following a mean duration of 2.9 ± 1.3 and 7.1 ± 3.0 months of use. Significant decreases in A1C and TDD were observed at both time points. Change in weight was significant (+2.3 lbs; P<0.0001) at the first time point, however, was not significant (+2.1 lbs; P=0.106) by the second time point. Switching to insulin delivery with V-Go proved clinically beneficial compared to prior therapy.


R.S. Hundal: Speaker's Bureau; Self; Valeritas, Inc., Abbott, Boehringer Ingelheim Pharmaceuticals, Inc., AstraZeneca, Novo Nordisk Inc., Amarin Corporation, Eli Lilly and Company, Merck & Co., Inc. S. Kowalyk: Speaker's Bureau; Self; Valeritas, Inc.. J. Cases: None. A. Al-Karadsheh: None. A.P. Wakim: Speaker's Bureau; Self; Versartis, Inc.. Research Support; Self; Valeritas, Inc.. M. Doyle: None. J.H. Sink: Other Relationship; Self; Janssen Pharmaceuticals, Inc., valeritas. Speaker's Bureau; Self; Novo Nordisk Inc.. Consultant; Self; Becton, Dickinson and Company. A. Spence: None. J.L. Brewer: Speaker's Bureau; Self; Valeritas, Inc., Janssen Pharmaceuticals, Inc. C.C. Nikkel: Employee; Self; Valeritas, Inc.. Stock/Shareholder; Self; Valeritas, Inc..

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.